


THE BIOJECT ADVANTAGE



- Increases Sales
- Offers Product Differentiation
- Broad Range of Capabilities
- 0.05 mL to 1.0 mL
- Eliminates Risk Associated with Needles
- Overcomes Patient Aversion to Needle Injections
- Patented Technology
- Extensive Patent Portfolio

- Examples of Published Studies

- | | |
|---|--|
| Vaccine | Clinical Cancer Research |
| Clinical Anesthesia | Innovations in Pharmaceutical Technology |
| Gene Therapy | Molecular Medicine |
| IBC Conference | Diagnostic Cytopathology |
| Anesthesiology | American Journal of Critical Care |
| The Pain Clinic | AACA/ BACA Conference Presented at the Mayo Clinic |
| International Journal of Clinical Pharmacology and Therapeutics | |
| The American Society of Tropical Medicine and Hygiene | |
| Journal of Oral and Maxillofacial Surgery | |
| Proceedings of the National Academy of Sciences U.S.A. | |
| Journal of the American Podiatric Medical Association | |
| New England Journal of Medicine | |
| Journal of Infectious Diseases | |
| Drug Delivery Technology | |

- Wide Range of Compounds Published

Bioject Inc.

7180 SW Sandburg St., Ste. 100 Tigard, OR 97223 USA

503-692-8001 www.bioject.com

Customer Service: 800-683-7221 ext. 4122

* Intradermal cleared for B2000
N 3062, Rev. D